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Abstract
Recent genome-wide association studies have identified multiple regions at 8q24 that confer
susceptibility to many cancers. In our previous work, we showed that the colorectal cancer (CRC)
risk variant rs6983267 at 8q24 resides within a TCF4 binding site at the MYC-335 enhancer, with
the risk allele G having a stronger binding capacity and Wnt responsiveness. Here, we searched
for other potential functional variants within MYC-335. Genetic variation within MYC-335 was
determined in samples from individuals of European, African, and Asian descent, with emphasis
on variants in putative transcription factor binding sites. A 2-bp GA deletion rs67491583 was
found to affect a growth factor independent (GFI) binding site and was present only in individuals
with African ancestry. Chromatin immunoprecipitation performed in heterozygous cells showed
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that the GA deletion had an ability to reduce binding of the transcriptional repressors GFI1 and
GFI1b. Screening of 1,027 African American colorectal cancer cases and 1,773 healthy controls
did not reveal evidence for association (odds ratio: 1.17, 95% confidence interval: 0.97–1.41, P =
0.095). In this study, rs67491583 was identified as another functional variant in the CRC-
associated enhancer MYC-335, but further studies are needed to establish the role of rs67491583
in the colorectal cancer predisposition of African Americans.
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Colorectal cancer (CRC) is a major public health problem worldwide, accounting for over
one million new cases each year. Currently, it is estimated that 147,000 new CRC diagnoses
and 50,000 deaths from CRC occur annually in the United States (1). A clear ethnic
disparity exists in the occurrence of CRC in the United States; African Americans have the
highest incidence and mortality rates for CRC among ethnic populations (2). Genetic and
environmental factors are suggested to contribute to the variation in CRC incidence.
Approximately 35% of the variation in CRC risk is attributed to genetic factors (3).
Mendelian CRC syndromes account for only 5% of all cases, and the remaining genetic
component of CRC is still largely unexplained. Recently, the “common disease–common
variant” model of predisposition was addressed by genome-wide association (GWA) studies.
To date, GWA studies, conducted in individuals of European descent, have identified 14
common genetic variants (rs6983267, rs4779584, rs4939827, rs16892766, rs10795668,
rs3802842, rs4444235, rs9929218, rs10411210, rs961253, rs6691170, rs10936599,
rs11169552, rs4925386) that confer increased susceptibility to CRC (4–9). In addition, a
recent fine mapping study identified two new independent CRC predisposition single
nucleotide polymorphisms (SNPs) near BMP2 (rs4813802) and BMP4 (rs1957636), and
suggested that the original CRC-associated SNP rs4779584, close to GREM1, actually tags
two functional SNPs. Thus, the original finding may have represented two independent
signals, now defined by rs16969681 and rs11632715 (10).
The 8q24 region, marked by SNP rs6983267, is by far the best-studied of the low-
penetrance CRC susceptibility loci. rs6983267 has been shown to associate also with
prostate cancer (11), and different regions at 8q24 gene desert have been found to confer
susceptibility to breast cancer (12), bladder cancer (13), and chronic lymphocytic leukemia
(14). It has been suggested that cancer predisposition is mediated by variants in tissue-
specific enhancer elements that control the expression of the MYC oncogene. In our
previous work, we showed that the CRC predisposition SNP rs6983267 affects a TCF4
binding site in the distal enhancer element, MYC-335, and the risk allele G creates a higher-
affinity TCF4 binding than the T-allele, resulting in stronger enhancer activity (15).
Pomerantz et al. (2009) demonstrated that the region containing rs6983267 interacts with the
MYC promoter, providing evidence that MYC is the target gene (16). The biological
mechanism underlying the CRC predisposition at 18q21 (rs4939827) and 8q23
(rs16892766) is similar (17–19). There, the CRC risks are caused by variants that change
activity of gene regulatory elements, leading to changes in SMAD7 and EIF3H/UTP23
expression. These studies have created novel insights into the molecular etiology of CRC.
Due to the importance of the 8q24 region in cancer predisposition, it is essential to scrutinize
in detail the CRC-associated enhancer MYC-335 at 8q24. Recent fine mapping studies have
shown that some of the known CRC loci may contain multiple risk variants, some of which
have proposed to be functional (10,19). Moreover, because GWA studies have been
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performed on Caucasian populations only, little is known about population-specific
differences in CRC predisposition. In this study, we characterized the genetic variation
within the CRC-associated enhancer MYC-335 at 8q24, aiming at identifying other
functional variants that could potentially act as CRC risk alleles. We sequenced the
MYC-335 enhancer in African, African American, Asian, and Caucasian samples and
investigated the role of rs67491583, which affected a transcription factor binding site, in
CRC predisposition in African Americans.
Materials and methods
Subjects
Caucasian control DNA samples used in the study included 188 anonymous Finnish blood
donors obtained from the Finnish Red Cross Blood Transfusion Service and 288 U.K. blood
donors obtained from Sigma-Aldrich (St. Louis, MO) (human random control DNA panels
1–3). African control samples consisted of 180 Yoruba (YRI) HapMap samples
(HAPMAPPT03 and HAPMAPPT04) provided by the Coriell Institute for Medical
Research (Camden, NJ). The HAP-MAPPT07 panel comprising 90 samples from people
with African ancestry in the southwestern United States was used as a representative of
AfricanAmerican population. A series of 36 blood donors from Korea was available as
Asian control samples (20).
Germline DNA specimens from 1,134 African American CRC cases and 1,732 controls
were available from different research centers in the United States. Case–control studies
were from University of North Carolina (UNC) (CRC, n = 410; controls, n = 418),
Multiethnic Cohort (MEC) (CRC, n = 240; controls, n = 431), University of Chicago (CRC,
n = 189; controls, n = 183), Ohio State University (OSU) (CRC, n = 96; controls, n = 192),
Cleveland Clinic/Case Western Reserve University (CRC, n = 105; controls, n = 160), and
University of Alabama (UAB) (CRC, n = 94; controls, n = 150). DNA samples from UNC,
MEC, and OSU were derived from blood (except three OSU cases: one from paraffin block,
two from buccal rinse). Samples from the University of Chicago were extracted from
formalin-fixed, paraffin-embedded normal tissue sections. Case DNAs from Cleveland
Clinic/Case Western Reserve University were from fresh frozen normal colon tissue and
controls from blood. DNA from UAB cases was derived from normal tissue surrounding
colon tumors, and controls were blood DNAs that were randomly selected from volunteers
within the UAB hospital system. In addition, 198 blood DNA controls were received from
the Howard University College of Medicine, Washington, DC. Also, 13 tumor DNAs
extracted from paraffin-embedded tissue samples were available from OSU. In addition, 44
normal and 26 tumor tissue DNA specimens from Korean colorectal carcinoma patients
were studied (20). Normal tissue DNAs from the Finnish CRC patients were selected from a
population-based series collected since 1994. All samples were derived with written
informed consent and approval from the respective institutions’ ethical review boards.
Cell lines
Epstein-Barr virus transformed B-lymphocyte cell line GM19240 was purchased from the
Coriell Institute for Medical Research and maintained in RPMI supplemented with 10%
fetal bovine serum (FBS). GM19240 was derived from a HapMap YRI individual. HeLa and
HEK293T cells were cultured in DMEM with 10% FBS, and LoVo cells were maintained in
DMEM + 1.5 g/L NaHCO3. All plasmid transfections were done with FuGENE HD
transfection reagent (Roche). Culture medium was changed 6 hours after transfection.
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The 1,255-bp MYC-335 enhancer element is located at 128,413,174-128,414,429 bp
(GRCh37, Ensemble 56: Sep 2009) in the human chromosome 8. This region was sequenced
to determine the genetic variation within the enhancer. The region was polymerase chain
reaction (PCR)-amplified from genomic DNA in two overlapping fragments. The primers
used in the reactions were as follows: F: 5′-AACTTTCCCAGCCTCGTTCT-3′ and R: 5′-
CCATGG GAAAATAGATGGCATA-3′, F: 5′-ATTCCTGACCTACCCCCAAA-3′ and R:
5′-GTTTTCAGGTGCGTGTGTGT-3′. The fragments were sequenced directly using
BigDye v3.1 (Applied Biosystems, Carlsbad, CA) sequencing chemistry and the ABI3730
automatic sequencer (Applied Biosystems). Sequence reads were analyzed using Mutation
Surveyor v3.24 software (Softgenetics, State College, PA). All sequences were also read
manually, and samples with ambiguous results were repeated.
Samples from Cleveland, OSU, and Howard University College of Medicine were
genotyped for rs67491583 (GA deletion) and rs6983267 using previously mentioned
primers. Case–control series from Chicago, MEC, UNC, and UAB were genotyped for
rs67491583 by sequencing, using primers F 5′-TCAATTTCATCTACGTGAAGAGC-3′ and
R 5′-TGCAGGATATCTTGGGAATGA-3′.
ChIP
ChIP was performed in HeLa and GM19240 essentially as described in Tuupanen et al. (15)
and Turunen et al. (21), using antibodies GFI1B (Rabbit Anti-GFI1B Polyclonal Antibody
H-150: sc-22795, Santa Cruz Biotechnology, Santa Cruz, CA), GFI1 (Rabbit Anti-GFI1
Polyclonal Antibody N-20: sc-8558, Santa Cruz Biotechnology), Histone H3 mono methyl
K4 (Rabbit Polyclonal Antibody, ab8895, Abcam, Cambridge, MA), or control IgG (normal
mouse IgG: sc-2025 or normal rabbit IgG: sc-2027, Santa Cruz Biotechnology).
Allele-specific binding of GFI1 and GFI1B to the rs67491583-containing site was assessed
by comparing the height of Sanger sequencing signal peaks from the wild-type allele and the
GA deletion-containing alleles in sequencing tracts. Fold changes were calculated relative to
input control. Primers targeting the rs67491583-containing fragments were: 5′-
GGAGATGCCAAAAAGCCAAT-3′ and 5′- AGAACAGGGGAAGCTGAACA-3′. The
primer used for Sanger sequencing was: 5′ - AGAACAGGGGAAGCTGAACA-3′.
For ChIP-by-sequencing (ChIP-seq), the precipitated DNA was repaired using Klenow and
T4 DNA polymerases and T4 polynucleotide kinase (MBI Fermentas, Latvia), and ligated to
adapters according to the manufacturer’s instructions (Illumina, San Diego, CA).
Subsequently, PCR amplified fragments of approximately 150–200 bp were sequenced
using the Illumina Genome Analyzer (University of Helsinki, Helsinki, Finland).
Sequencing reads (36 bp) were mapped to the human genome (NCBI36) using Maq software
by Heng Li, version 0.6.5. Only high-quality reads that could be reliably mapped (mapping
quality score at least 30) were accepted, resulting in a total of 15.1 and 4.8 million reads
from GFI1 GM19240 ChIP and IgG control samples. Each read was then extended to a
sequence of 170 bp, and height was determined at each position as the number of
overlapping sequences.
This analysis yields a maximum peak-width of 250 bp for one occupied GFI1 site (120 bp in
both directions from an approximate 10-bp site). The positions with a height of 10 or more
were defined as peaks. For each peak, the total number of sequences in the continuous
region of four or more overlapping sequences was compared with the number of sequences
in the same region in the IgG control. The probability of observing the difference between
the sequence counts in the ChIP sample and IgG control by chance was estimated using
Winflat program 49. The program was originally developed for digital gene expression
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analysis, and it can take into account the uncertainty associated with low sequence counts
and the difference in the total amount of ChIP and IgG control reads. In total, 16,700 GFI1
peaks in GM19240 with a height of >10 and P < 0.05 were observed.
Luciferase assay
For luciferase reporter assays, a previously generated reporter construct containing
MYC-335 enhancer with G allele of rs6983267 was used (15). A reporter construct
containing the GA deletion allele was created by site-directed mutagenesis. hGFI1B cDNA
was over-expressed in HEK293T, HeLa, and LoVo cells. The 1,406-bp sized, element-
containing reporters were transfected into cells together with a Renilla luciferase control
reporter (Promega, Madison, WI). Luciferase activities were measured at 32 hours with the
DualLuc kit (Promega). Relative luciferase activities were calculated by dividing the firefly
luciferase counts with the Renilla controls, and the results were normalized to the wild-type
allele.
Analysis of allelic imbalance
Allelic imbalance was analyzed in tumor DNA of 13 CRC cases that were heterozygous for
the GA deletion. Normal and tumor DNA from the same patient was sequenced using
primers 5′-TCAATTTCATCTACGTGAAGAGC-3′ and 5′-
TGCAGGATATCTTGGGAATGA-3′, and AI was scored by comparing the allelic peak
ratios in tumor DNA respective to the normal tissue.
Statistical analyses
We expected heterogeneity across study groups; therefore, we used boxplots to identify
possible outliers in the allele frequency data (Table 2, Supplementary Figure S1) (22). Case
series UAB was identified as an outlier and was excluded from further analysis. African
American populations are highly heterogenous; therefore, genotype counts were calculated
separately for different case–control series. Association analyses were performed by
combining genotyped counts from all the sample series. Association analyses were
performed using R software (v2.10.1). Pearson’s chi-square test was used to calculate P-
values, odds ratios (ORs), and the associated confidence intervals (CIs). Power calculations
were performed at http://statpages.org/proppowr.html.
Relationship between rs67491583 genotype and MYC expression
To examine a relationship between the rs67491583 genotype and the expression level of
MYC, publicly available exon array gene expression data from 89 YRI HapMap Epstein-
Barr virus–transformed lymphoblastoid cell lines were used (GEO GSE7761) (23). To
discard erroneous probes, probe set intensities were generated using the Brainarray (v.
12.1.0, ENSG) custom CDF file (24). The data was normalized using RMA normalization
provided in exonmap package (v1.0.07) for R (v2.9.0). A two-sided t test assuming equal
variance in the groups was used to compare MYC expression (ENS-G00000136997_AT)
between the wild-type (n = 75) and heterozygous (n = 14) cell lines.
Another sample set was obtained from OSU and included B-lymphocyte cell line pellets in
Trizol from 40 healthy individuals. Twenty of 40 were wild-type for rs67491583, 19 were
heterozygotes, and 1 was a homozygote. Total RNA was extracted with standard Trizol-
based protocol, and 800 ng of total RNA was reverse transcribed to cDNA using the
Promega MMLV enzyme. Relative expression of MYC was determined with TaqMan
chemistry and the ABI Prism 7500 sequence detection system using assays for MYC
(Hs00153408_m1) and endogenous control PGK (Hs99999906_m1) (both from Applied
Biosystems).
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Sequencing the MYC-335 element (Supplementary Table S1) in 727 control samples (247
U.K., 174 Finnish, 180 HapMap YRI, 90 HapMap African Americans, 36 Koreans) revealed
13 variants, of which 6 were known (rs6983267, rs34835043, rs73706717, rs67180956,
rs7008058, rs67491583) and 7 were new variants (Table 1). Three of the novel variants
(novel 3, 4, 5) were present in only one sample each. Allele frequencies of the variants
varied between populations. Our previous notion that the CRC predisposition SNP
rs6983267 affects the TCF4 binding site at the MYC-335 prompted us to particularly look
for variants that affected any of the 24 other enhancer element locator (EEL)-predicted
transcription factor (TF) binding sites within the MYC-335 enhancer (14). Indeed, two such
variants were identified (Table 1, Supplementary Table S1). rs67180956 was located at the
first nucleotide of the broad complex 3 binding site TGTTTTGTTTA; however, this site is
not conserved in mouse (GTTATAGTTTT) and, therefore, was not studied further.
rs67491583, which is a 2-bp deletion, mapped to a growth factor independent (GFI) binding
site CAGAGATTGC (GRCh37: chr8: 128414228-128414237). The deletion affected GA
nucleotides at the fifth and sixth position of the binding sequence (CAGAGATTGC).
rs67491583 has been previously found in the genome of Craig Venter; however, no
population genetics were available for this variant, and it has not, to our knowledge, been
reported elsewhere. In our data, the deletion was found only in samples with African origin
and was absent in 421 Caucasians and 36 Koreans. Allele frequency of the deletion was
8.9% in HapMap YRI samples and 5.6% in HapMap African American samples (Table 1).
Due to the low number of control samples representing Asian population, we screened 70
Korean CRC patients (44 normal and 26 tumor DNAs) for the GA deletion. None of these
displayed the GA deletion. In addition, no GA deletions were identified among 79 Finnish
CRC patients.
The GFI binding sequence CAGAGATTGC at the MYC-335 element contains sequence
GATT (AATC) that is a core binding motif for GFI proteins, GFI1 and GFI1b (25).
According to the affinity matrix available in the JASPAR database, the identified binding
sequence (CAGAGATTGC) differs slightly from the consensus binding sequence of GFI
(CAGTGATTTG). The GA deletion at the EEL-predicted binding site results in generation
of a weaker GFI site that has a 5.5-fold lower affinity than the GA-containing sequence. The
identified GFI1 binding sequence is highly conserved in evolution. According to Ensemble
multispecies alignment, exactly the same sequence is present in chimpanzee, orangutan,
rhesus macaque, cow, rat, and mouse genomes. Dog and horse show one base pair
difference in the binding sequence (data not shown).
We assessed whether the GA deletion has an effect on TF binding in cells. We genotyped
CRC cell lines RKO, GP5D, HCT8, HUTU80, HCA7, LS174T, LS180, HCT116, VACO5,
SW480, LoVo, and CCL231 as well as cervical adenocarcinoma cell line HeLa for the GA
deletion rs67491583. All the CRC cell lines were wild-type for rs67491583. HeLa cells that
originate from a 31-year-old African American woman were found to be heterozygous for
rs67491583. We tested the effect of the deletion on GFI binding by conducting chromatin
immunoprecipitation (ChIP) in heterozygous cell lines HeLa and GM19240, using
antibodies for GFI1, GFI1B, H3K4me1, and p300 (Figure 1, Supplementary Figure S1).
GFI1 proteins are not expressed in HeLa; therefore, GFI1B was transiently over-expressed
on these cells before the experiments. Sanger sequencing of the input and
immunoprecipitated DNA indicated that GFI1B bound more strongly to the wild-type allele
than to the mutant allele (Figure 1A). Similarly, in the lymphoblast cell line GM19240,
endogenous GFI1 and GFI1B preferred to bind to the wild-type allele (Figure 1B). In turn,
H3 monomethyl Lysine 4 (H3K4me1), a correlate of enhancer activity (26), was
preferentially found in the GA deletion-containing allele of GFI1B-expressing HeLa cells
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(Figure 1C). We observed an approximately twofold decrease in H3K4 monomethylation in
the allele that binds to GFI, consistent with the action of GFI as a repressor. Although the
effect is not all-or-nothing, it is quite large considering that only a single TF binding site is
affected in a regulatory element that binds to many TFs. H3K4me1 was also tested in
GM19240; however, the binding was balanced between the alleles. This is probably because
GM19240 is a lymphoblastoid cell line, and it is likely that this tissue-specific enhancer (15)
is not functional in lymphoblasts. However, p300, another correlate of enhancer activity,
preferred to bind to the wide-type allele in GFI1B-expressing HeLa cells (Supplementary
Figure S2), suggesting that the GA deletion may also decrease transcriptional co-activator
binding. To gain a comprehensive picture of GFI1 occupancy at MYC-335, we performed
ChIP-seq in GM19240 cells (Figure 2). ChIP-seq indicated two peaks within the 2,000-bp
genomic fragment containing MYC-335 (Figure 2).
To evaluate the effect of rs67491583 on MYC-335 enhancer activity, we generated a
luciferase reporter construct containing the GA deletion. Wild-type and GA deletion-
containing constructs were transfected into HEK293T, HeLa, and LoVo cells with or
without GFI1B. cDNA and luciferase activity was measured after 32 hours. Consistent with
weaker co-activator binding by the GA-deletion allele (Supplementary Figure S2), in the
absence of GFI1B co-expression, the MYC-335 reporter with the GA deletion showed
weaker luciferase activity than the wild-type reporter in LoVo cells (P = 9.28 × 10−5)
(Supplementary Figure S3). When GFI1B was co-expressed, the GA deletion-containing
enhancer displayed significantly increased reporter activity in HEK293T (P = 9.7 × 10−6),
HeLa (P = 1.8 × 10−8), and LoVo cells (P = 0.0005) (Figure 3). These results suggest that in
the absence of GFI, the GA deletion is a somewhat weaker enhancer, but in the presence of
GFI, the GA deletion is more active as it binds less repressor.
The GA deletion was present only in samples from African descent; therefore, we tested
whether it could influence CRC susceptibility in African American individuals. A total of
1,027 of 1,134 (90.6%) CRC cases and 1,683 of 1,732 (97.2%) controls were included in the
association analyses after genotyping and outlier detection. Including the 90 African
American HapMap samples, the total number of genotyped controls was 1,773. After
combining the data from all the different sample series that could be made available for the
study (Table 2), the allele frequency of the deletion was higher in CRC cases (9.9%) than in
controls (8.6%); however, this difference did not reach statistical significance (P = 0.095;
OR: 1.17, 95% CI: 0.97–1.41). Table 2 shows that allele frequencies varied between
different sample series, suggesting heterogeneity across study groups. It was estimated that
the study had 80% power to detect variants with minor allele frequencies of 10% and ORs of
1.36 at significance level of 0.05, but only 40% power to capture variants with frequencies
of 10% and ORs of 1.2. GA deletion homozygotes were found to be more common among
cases (12/1,027 = 1.7%) than controls (12/1,773 = 0.7%) (Table 3), suggesting that CRC
risk may be further increased in GA deletion homozygotes (OR: 1.73, 95% CI: 0.76–3.95).
In our previous reports, we have shown that during CRC tumor evolution, the CRC risk
allele G of variant rs6983267 is selected for through increases in copy number (15,27).
Similarly, allelic imbalance at the GA deletion was analyzed in the tumor DNA of 13
heterozygous cases. Copy number increase was detected in 4 of 13 tumors (31%), and 3 of 4
AI events affected the mutant allele.
Finally, we studied the relationship between the rs67491583 genotype and MYC expression.
We used gene expression data determined on 89 YRI HapMap lymphoblastoid cell lines
(23), as well as MYC expressions measured with real-time quantitative PCR (qPCR) in
lymphoblastoid cell lines of 40 African American control individuals. We could not detect
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an association between the rs67491583 genotype and MYC expression either in the
microarray gene expression data (P = 0.17) or in the qPCR data (P = 0.95).
Discussion
In our previous work, we used a computational tool, enhancer element locator, and
identified an evolutionary conserved enhancer element MYC-335 that contains CRC
predisposition SNP rs6983267 (15). rs6983267 resides at a TCF4 binding site, and the CRC
risk allele G has the ability to enhance TCF4 binding and promote Wnt signaling. Here, we
have sequenced through the MYC-335 enhancer in individuals with European and African
descent and identified a GA deletion (rs67491583) at a putative GFI binding site.
Interestingly, rs67491583 occurred only in samples from individuals of African origin.
The GA deletion rs67491583 resides 927 bp downstream from the SNP rs6983267. The
functional data presented in this study show that the GA deletion has an effect on
transcription factor binding; it reduces the binding of GFI proteins to the MYC-335
enhancer. GFI1 and GFI1b are zinc finger transcriptional repressors that function by binding
to DNA elements containing a core AATC sequence (25). GFI1 and GFI1b are functionally
very similar and both play an important role in hematopoietic development and
lymphomagenesis. Gfi1b is required for the development of erythroid and megakaryocytic
lineages (28). Mice lacking functional Gfi1 are neutropenic, and heritable GFI1 mutations in
humans cause severe congenital neutropenia (29,30). GFI proteins can also function as
proto-oncogenes. Gfi1 is a frequent target of retroviral integration in T and B cell
lymphomas, leading to transcriptional activation of the Gfi1 gene. Gfi1b also plays an
essential role in erythroleukemia and megakaryocytic leukemia (31). Additionally, Gfi1 has
been shown to regulate differentiation of nonhematopoietic tissues, such as inner ear hair
cells, lung neuroendocrine cells, and intestinal epithelial cells (32–34). In the mouse
intestine, expression of Gfi1 is found in cells throughout the developing intestine (33). In
mature small and large intestines, expression is detected mainly in the crypts. Gfi1 functions
downstream of Math1 in early progenitors, contributing to lineage determination of
intestinal epithelial progenitors. Because Gfi1 is important in intestinal epithelial cell
proliferation, a role in intestinal malignancies is feasible. Variants rs6983267 and
rs67491583 might contribute to colorectal neoplasia by increasing the activity of the
MYC-335 enhancer and MYC expression and, in that way, disturb the intestinal
homeostasis. Consistently, MYC has been described as a GFI1 and GFI1b target gene in
myeloid cells (35,36).
We failed to detect an association between rs67491583 and CRC risk in African Americans.
Due to low frequency of the deletion in the African American population (~10%), an even
larger sample size would have been needed to obtain statistical power to detect significant
association. Moreover, African Americans are genetically a highly heterogenous group and,
without adjustment for population stratification association, analyses might give spurious
results. Previous studies have shown conflicting results about the contribution of rs6983267
to CRC risk in African Americans (37,38).
The hypothesis that rs67491583 affects CRC predisposition is intriguing. First, both
MYC-335 variants rs6983267 and rs67491583 affect transcription factor binding sites and
are highly differentially distributed in different ethnic populations. Based on the HapMap
data, the frequency of G allele of rs6983267 is highest in Africa (~97%), whereas moving on
from Africa the frequency is reduced (~82% in African Americans, 50% in Caucasian
populations, 39% in Han Chinese, and 29% in Japanese). In this study, a similar
phenomenon was detected for the GA deletion at the GFI site. The allele frequency is
approximately 10% in African Americans, but in individuals of European descent the GA
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deletion is very rare. These observations suggest that both alleles are functional and under
selective pressure from environmental exposure. Second, the predicted effect of the G allele
at the TCF4 binding site and the GA deletion at the GFI binding site on MYC expression is
similar. The CRC risk allele G of rs6983267 enhances TCF4 binding and the GA deletion
reduces repressor binding, which should lead to increased expression of a target gene.
Evidence obtained from this and previous works indicate that the MYC-335–bearing G
allele of rs6983267 in concert with the GA deletion at the GFI1 binding site is a stronger
enhancer than the “wild-type” element. The stronger form of the enhancer—potentially
leading to increased expression of MYC and increased proliferation—could provide
protection in certain environmental challenges, such as tolerance to gastrointestinal
infections.
Taken together, we have characterized in detail the genetic variation within the MYC-335
regulatory element and have identified a population-specific functional variant at the GFI
binding site. We were unable to detect significant association between rs67491583 and CRC
risk in African Americans. However, our study power was limited and more extensive
studies are needed to detect the putative association. In theory, the strong predominance of
the G allele in individuals with African origin together with the disrupted GFI site could, in
part, explain the high CRC incidence in African Americans. Importantly, the low incidence
of CRC in Africa provides hope that the effects of these two candidate risk alleles can be
controlled by environmental and lifestyle factors, such as diet. Further work to investigate
the contribution of MYC-335 variants in neoplasia, as well as normal homeostasis, is highly
warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ChIP followed by PCR and Sanger sequencing for rs67491583. (A) In HeLa cells,
ectopically over-expressed GFI1B favors binding to the wild-type allele of rs67491583.
Sanger-sequencing of anti-GFI1B precipitated DNA (αGFI1B) reveals that the wild-type
allele (TC) is enriched by the GFI1B precipitation when compared with the input DNA
(Input). (B) In the GM19240 lymphoblast, endogenous GFI1 (αGFI1) and GFI1B (αGFI1B)
both prefer to bind to the wild-type allele (TC). (C) In HeLa cells over-expressing GFI1B,
Sanger-sequencing of anti-histone H3 monomethyl Lysine 4 precipitated DNA
(αH3K4me1) reveals that the risk-allele (TG) is enriched by the H3K4me1 precipitation
when compared with the input DNA (Input).
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GFI1 occupancy in this genomic region in GM19240 lymphoblast cells. The 2 kb region at
chromosome 8q24 with the highest number of overlapping sequences as determined by
ChIP-seq. rs67491583, indicated by a red line, resides near one of the two peaks. The blue
line marks the other EEL-predicted GFI binding site in this region.
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Enhancer activity is changed when GA nucleotides were absent at rs67491583. The GA
deletion allele-containing enhancer fragment (risk allele) displays a slightly but statistically
significantly higher enhancer activity than wild-type allele-containing enhancer fragment
(WT) in luciferase assay in GFI1B cDNA transfected HEK293T, HeLa, and LoVo CRC
cells. Error bars indicate one standard deviation (n = 6).
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Table 1
Variants within MYC-335 revealed by sequencing 727 control samples
Minor allele frequency
Variation Type Location chr8 TF binding site U.K. Finland YRI SW AFAM Korea
rs6983267a G>T 128413305 TCF4 0.541 0.535 0.977 0.822 0.389
rs34835043 A>G 128413389 0.038 0.056 0.069 0.028 0.069
rs73706717 T>C 128413510 0 0 0.117 0.128 0
Novel 1 G>A 128413593 0 0 0.017 0.017 0
Novel 2 G>T 128413783 0.081 0.115 0 0.022 0
rs67180956 T>C 128413809 Broad Complex 3 0.041 0.057 0.138 0.094 0.069
Novel 3 G>A 128413829 0 0 0.003 0 0
rs7008058 T>C 128413978 0 0 0.117 0.128 0
Novel 4 G>A 128413985 0 0.003 0 0 0
Novel 5 C>T 128414065 0 0.003 0 0 0
rs67491583 Del GA 128414232e128414233 GFI1 0 0 0.089 0.056 0
Novel 6 C>T 128414371 0.067 0.075 0.028 0.017 0.028
Novel 7 G>C 128414372 0 0 0.006 0 0
a
Frequency of the risk allele G is presented.
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Table 2




test P-valueaTotal Wt Het Hom Frequency
UNC
 CRC 408 331 74 3 12.1 0.78
 Controls 410 338 70 2 10.9 0.56
MEC
 CRC 240 200 38 2 8.8 1.00
 Controls 431 368 61 2 7.5 1.00
Chicago
 CRC 182 147 30 5 11 0.05
 Controls 176 137 36 3 11.9 1.00
OSU
 CRC 95 81 13 1 7.9 0.62
 Controls 188 161 26 1 7.4 1.00
Cleveland
 CRC 102 76 25 1 13.2 0.69
 Controls 153 125 27 1 9.5 1.00
Washington
 Controls 189 156 31 2 9.3 0.70
UAB
 Controls 136 115 20 1 8.1 1.00
HAPMAPPT07
 Controls 90 80 10 0 5.6 1.00
Total
  CRC 1027 835 180 12 9.9 0.60 P = 0.095
  Controls 1773 1480 281 12 8.6 0.77 OR = 1.17 95% c.i 0.97–1.41
a
Pearson’s Chi-squared test with simulated P-value (based on 1e+06 replicates).
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Table 3
Genotype associations of rs6749158 in African American samples
CRC Controls P-value OR 95% CI
Hom vs. het/wt 12/1015 12/1761 0.17 1.73 0.76–3.95
Hom/het vs. wt 192/835 293/1480 0.14 1.16 0.95–1.42
Hom vs. wt 12/835 12/1480 0.16 1.77 0.77–4.04
Het vs. wt 180/835 281/1480 0.23 1.14 0.92–1.39
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